Member Info for Supermobileman

Here we go again. You clearly can't write, now you can't read.

You can't even grasp a basic English language.

Nowhere, in words, in the TR1 does it say they sold their 3% in their holding in IMM. As I said before, your interpretations are ambiguous and lack of clarity.

It would be acceptable if you have said "Lanstead has sold 20% of their 80.5m shares holding in Immupharma, resulting in a reduction of 16.13% to 12.99% equity stake in Immupharma as a whole"

Don't try to deflect what you said.

You said, " they sold 3% of their holding".

What percentage of shares do Lanstead hold of the company? Then they haven't sold 3% of their holding.

Stupid dumb a..

Peterpharma,

You are still referring Lanstead having sold 3%.

You said on your posts,

"they sold 3% of their holding" and "If Lanstead were not used then at least 3% would not have been sold onto the market with another 13% to come".

This is in my opinion ambiguous and wrong interpretation. It is misleading and should be avoided.

These statements implying to me, your saying Lanstead hold all 499.7m shares in circulation. You have to. Because to get the figure 15.6m shares Lanstead sold, it have to be 3% (3.14%) of 499.7m.

Lanstead have not sold 3% of their holding. They sold approximately 20% of their holding.

So what is it? Lanstead sold 3% of their 80.5m holding??! or Lanstead sold 3% of their 499.7m holding?

Lanatead held 80.5m.

Lanstead now has 64.9m.

That's a reduction of nearly 20% of Lanstead's total holding.

Lanstead sold nearly 20%.

No your wrong, Lanstead had 28.7m shares which was 6.90% of 416.4m shares in circulation before the latest fundraise as of February.

After the latest fundraise, Lanstead then had 80.5m shares which was 16.13% of 499.7m shares in circulation.

On this latest RNS, Lanstead now has 64.9m shares which is now 12.99% of 499.7m shares in circulation.

Lanstead sold nearly 20% after the fundraise since February.

There are several reasons why Avion haven't 'started' phase 3 trial yet. I will give two of those in my opinion.

First reason, the FDA requires the USA phase 3 in lupus trial to be run in conjunction with the rest of the world trials so that diverse ethnic groups are included. This can be a requirement but not mandatory. We don't know Avion/Immupharma requirements with the FDA on this.

If this is the case, remember Avion signed the licensing deal for Lupuzor in lupus for USA only, then Avion ain't going to pay for the trials in the rest of the world if I remember correctly unless it stated in their licensing deal they have to. Therefore the waiting is for the rest of the world partner to come on board and run the trials in unison with Avion.

Second reason, Avion are considering selling or sublicensing the Lupuzor rights in lupus for USA to a third party. This is allowed as long as the licensing agreement with Immupharma allows it to do so. We don't know the full agreement.

One thing for sure, I do not think for a moment Avion would just hand the keys back and walk away for nothing. Where are you going to find another licensing deal like this paying dirt cheap jumble sale price for a potential product worth billions.

There are other reasons but I haven't got all night.

Tiger16,

You are a good laugh on this board with you and your city buddies.

If you post this message " I gaurantee you a deal will be signed by the end of this week.....", and if it doesn't, post it again the following week and all subsequent weeks thereafter until it has. Then you can't go wrong. You're bound to get it right someday.

You remind me of Pinocchio. Everytime you speak your nose grows longer.

Lollywally,

Tim promised nothing. Tim never said he promised this and promised that. It's coming from your own grumpy disillusion mind.

Correction,

Tiger16,

Who's selling? What advise?

Tiger16,

Whose selling? What advise?

The interested potential partners have only got hold of the proof of data a day or two ago. They'll need to analyse it. Those who are interested to proceed will put in offers. If there are more than one bidder (which I expect will be), then we could have counteroffers. Lawyers on all sides will be submitting written offers and counteroffers back and forth until the last one standing acceptable to Immupharma. This could take some time.

Correction, "graps" should have read "grabs"

To reiterate my point on refusal rights of Avion on all other indications in U.S. only, the deal Avion done on lupus for U.S licensing rights of $25m for the trial and $80m for milestone payments I think it was, does not includes for all other indication rights in the U.S. where no further payments are needed.

As I said, Avion have the rights to have first say on all other indications in the U.S. only and if they wish to proceed to clinical trials, they have to go through the usual licensing process route and pay the market rate for each indication.

The U.S. rights for all other indications are not free of charge.

To support my view, Immupharma are currently now as it stand, looking/ negotiating for WORLDWIDE rights for the CIDP indication. Yes, worldwide rights and NOT rest of the world rights (minus the U S.).

The worldwide rights for CIDP is up for graps.

Immupharma wouldn't be allowed to negotiate the worldwide rights if Avion have the U.S. rights would they? Immupharma is doing it because Avion have not exercised their option to do so. My guess, probably Avion can't afford it or it was too much risks to take on for a minor pharma.

Nolupus,

To further my argument, what your saying in your last post about the refusal is if a potential partner offered, let say, $1B and Avion offered $200M, Avion have the rights to refuse potential partner $1B offer for Immupharma but Immupharma must take the Avion's offer.

Then what's the point Immupharma going to all these talks for a deal if Avion is simply going to refuse it because Avion offer is the only one Immupharma allowed to take.

Totally absurd and bonkers.

Nolupus,

Could you elaborate further when you said "first refusal on other indications (outside lupus)" and "obstacle to any future deal".

My interpretation is Avion has the 'rights', that is to say first say, if they want to license other indications, in the U.S. only, before Immupharma can talk to other potential partner(s). But they have to pay the market rate.

It is in my opinion, absolutely absurd they have the refusal/veto rights. There were nothing in the past RNS mentioned about this. If Avion really do have this refusal rights, Immupharma would have already had held talks with them and settled it. Again, that is to say Avion has first say of any other indications they want to license in the U.S. only. If not, Immupharma can embark on talks with new potential partner(s). And that is what Immupharma have been doing and is doing.

If I categorise pharmas into minor, medium or major groups, I would put Avion in the minor group. Because that's what they are. Yes, they are a private company, so financially nothing much is know about them. But I definitely do not believe they have the financial clout of the big pharmas. That is to say, they can't outbid the big pharmas. Asked yourself why Avion only took the U.S rights to lupus and not the worldwide rights as is the vast majority norm in the pharma licensing world. Is it because having worldwide rights would cost more and is out of their reach? Or is it because they are derisking, by just taking the U.S. rights?

As I said before not long ago, Avion got lucky. With further advanced work Immupharma have done now since Avion deal and Lupuzor goes on to became multi-billions, Avion has got the deal of the century. Where can you find such a deal in the pharma world paying peanuts and doing, well bugger all (on further advancing P140 developments).

Lords wally,

You said, "If you believe Tim, this is a Hold/Buy. If you don't, it's a sell. Simples."

It's plain obvious you don't believe or trust Tim. So why don't you sell?

What a pathetic hypocrite.

word on the street came to me is that lordloadsof*******s is a irritating parasite. a spray of disinfectant is needed on this board.

As we know the phase 3 requires two mandatory separate trials each with equal number of patients to be determined by the FDA.

Before the last phase 3 started, when Dimitri Dimitriou was the CEO, the FDA have earmarked Lupuzor phase 3 with two trials as per norm and each with 400 patients.

Dimitriou requested to the FDA to have Lupuzor phase 3 done with only one trial AND to have the number of patients reduced to half the requested patients of only 200 patients.

The FDA was so impressed with Lupuzor's safety profile, they agreed.

So it was ONLY one trial with reduced patients of 200.

Supportive or not?

Everytime I read Nolupus' posts, I've farted.

Avion got the rights to the US market for the lupus indication only. They have no rights for the rest of the world. Nor have they got any rights for all other indications Immupharma decide to go into. Immupharma currently own the CIDP indication 100% worldwide rights as it stand now. This CIDP is , to me, Immupharma's crown in the jewel.

Avion got lucky. They struck the deal when Immupharma was down on its knees and was vulnerable after last phase 3 trial. The work Immupharma carried out since then and now have, which was not available at the time, Avion could not possibly got the deal they have now, paying peanuts really in pharma licensing standard. If Lupuzor does succeed and go on to have sales in multi billions, Avion has got the deal of the century in the pharma world.